CA
NZ
UK
AU
IND
US
ADC Therapeutics (NYSE:ADCT) is working to build on its approved lymphoma treatment while advancing a pipeline of antibody-drug conjugates. The company reported second-quarter 2026 results that narrowed its loss, though questions around a key confirmatory study tempered the picture.
Atossa Therapeutics (NASDAQ:ATOS) is advancing a differentiated approach to breast-cancer treatment and prevention. The company is building a body of evidence for its lead candidate across multiple settings, with the path forward running through clinical data and regulatory progress.
●Pediatric designation plans:On June 18, 2026, Cadrenal announced plans to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease.
● The company's lead drug simufilam failed to demonstrate benefit in Alzheimer's disease trials.
Actuate Therapeutics (NASDAQ:ACTU) has delivered the kind of clinical data that can transform a micro-cap biotech's prospects, reporting a striking survival benefit for its lead drug in one of oncology's most difficult indications. Investors are now weighing whether the company's validation in metastatic pancreatic …
An initiation of coverage means a broker has begun publishing formal research on a company and has assigned a rating and a valuation objective for the first time. The rating and the objective represent that firm’s own view. They are not company guidance, and …
Transactions of this type are disclosed on Form 4, the filing required under Section 16(a) of the Securities Exchange Act for directors, officers and holders of more than 10 per cent of a registered class of equity. The filing is due within twoBusinessdays of …
The distinction sits at the centre of this result. Statistical significance answers whether an observed difference is unlikely to be chance. Magnitude of effect answers how large that difference is. A trial can clear the first test and still produce an effect size that …
An at-the-market programme allows a company to sell new shares into the open market over time at prevailing prices through a designated agent, rather than raisingCapitalin a single marketed offering. It gives flexibility on timing and avoids the discount typically attached to a placement. …
The two figures do different work. USD 400 million is capital Biohaven receives now. The USD 795 million total is the ceiling if every milestone in the agreement is achieved, which places roughly USD 395 million in contingent payments beyond the immediate amount. Royalties …
Please wait processing your request...